NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Short Interest Down 20.0% in November

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,200 shares, a decline of 20.0% from the October 31st total of 1,500 shares. Based on an average trading volume of 4,400 shares, the short-interest ratio is currently 0.3 days.

NRx Pharmaceuticals Stock Performance

NASDAQ NRXPW traded down $0.00 on Friday, reaching $0.05. The stock had a trading volume of 8,318 shares, compared to its average volume of 15,841. NRx Pharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.39. The firm has a fifty day moving average of $0.06 and a two-hundred day moving average of $0.07.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.